Koninklijke Philips (PHIA) CMD 2026 summary

Strategic direction and growth ambitions

• Entering a new phase focused on profitable growth, aiming to improve 2.5 billion lives by 2030 and deliver mid-single-digit sales CAGR and mid-teens margins by 2028, with €4.5–5 billion cumulative cash generation over the period.

• Strategy built on three pillars: focused value creation with segment-specific strategies, innovation growth leveraging AI and platforms, and disciplined execution with commercial excellence.

• Capital allocation prioritizes organic growth, stable dividends, selective M&A, and periodic share buybacks, with a strong focus on high-return businesses like monitoring and interventional.

• Portfolio management has shifted from a 70/30 approach to tailored strategies for each segment, targeting growth and margin expansion across all businesses.

• ESG ambitions for 2030 include improving 2.5 billion lives, significant emissions reductions, and embedding sustainability in business models.

Innovation, platforms, and operational excellence

• Accelerated innovation pipeline includes world-firsts in imaging (helium-free 3T MRI, AI-embedded CT), breakthrough interventional platforms (Azurion AI), and next-gen monitoring and consumer health solutions.

• Platform strategy integrates hardware, software, data, and AI, leveraging a global installed base of 2.5 million systems and partnerships with AWS, NVIDIA, and leading clinical institutions.

• Productivity programs delivered €2.5 billion in savings over three years, with a new €1.5 billion program targeting further cost competitiveness, leaner central functions, and AI-driven efficiencies.

• Commercial and service excellence enhanced by digital tools, data-driven performance management, and strategic partnerships, driving improved win rates and customer outcomes.

• Quality, patient safety, and supply chain resilience have been strengthened, with significant progress on regulatory and recall-related actions.

Segment performance and financial outlook

• Diagnosis & Treatment targets mid-single-digit growth and mid-teens margins by 2028, driven by margin-accretive innovation, commercial execution, and market mix, with Image-Guided Therapy aiming for low-20s EBITDA margin.

• Precision Diagnosis expects low to mid-single-digit growth and low-teens margins, leveraging leadership in ultrasound, helium-free MR, and AI-powered imaging platforms.

• Connected Care is positioned for mid-single-digit growth and mid-teens margins, led by monitoring and enterprise informatics, with strong service and software expansion.

• Personal Health aims for mid-single-digit growth and high teens margin by 2028, focusing on premiumization, innovation, and channel expansion.

• Free cash flow guidance is €1.3–1.5 billion in 2026 and €4.5–5 billion cumulatively, with continued deleveraging and ROIC targeted at mid-teens by 2028.